6ROP image
Deposition Date 2019-05-13
Release Date 2019-12-04
Last Version Date 2024-11-13
Entry Detail
PDB ID:
6ROP
Keywords:
Title:
KS-MAT DI-DOMAIN OF MOUSE FAS WITH OCTANOYL COA
Biological Source:
Source Organism:
Mus musculus (Taxon ID: 10090)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.70 Å
R-Value Free:
0.23
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
C 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Fatty acid synthase
Gene (Uniprot):Fasn
Chain IDs:A, B, C, D
Chain Length:852
Number of Molecules:4
Biological Source:Mus musculus
Primary Citation
Type I fatty acid synthase trapped in the octanoyl-bound state.
Protein Sci. 29 589 605 (2020)
PMID: 31811668 DOI: 10.1002/pro.3797

Abstact

De novo fatty acid biosynthesis in humans is accomplished by a multidomain protein, the Type I fatty acid synthase (FAS). Although ubiquitously expressed in all tissues, fatty acid synthesis is not essential in normal healthy cells due to sufficient supply with fatty acids by the diet. However, FAS is overexpressed in cancer cells and correlates with tumor malignancy, which makes FAS an attractive selective therapeutic target in tumorigenesis. Herein, we present a crystal structure of the condensing part of murine FAS, highly homologous to human FAS, with octanoyl moieties covalently bound to the transferase (MAT-malonyl-/acetyltransferase) and the condensation (KS-β-ketoacyl synthase) domain. The MAT domain binds the octanoyl moiety in a novel (unique) conformation, which reflects the pronounced conformational dynamics of the substrate-binding site responsible for the MAT substrate promiscuity. In contrast, the KS binding pocket just subtly adapts to the octanoyl moiety upon substrate binding. Besides the rigid domain structure, we found a positive cooperative effect in the substrate binding of the KS domain by a comprehensive enzyme kinetic study. These structural and mechanistic findings contribute significantly to our understanding of the mode of action of FAS and may guide future rational inhibitor designs.

Legend

Protein

Chemical

Disease

Primary Citation of related structures